Quarterly Education & Business Meeting! Thursday, December 11, 2025. "Leqembi: Long-Term Treatment Choice for Early Alzheimer's Disease" - Sponsored by Eisai and Biogen - The maximum capacity has been reached. The waiting list has been enabled

The maximum capacity for this event has been reached.  However, the waiting list has been enabled.  If someone cancels, you will receive a notification.  We apologize for any inconvenience this may have caused.  

The program will begin promptly at 6:00pm followed by the GLC Business Meeting.

This program will:
Review the Prescribing Information for LEQEMBI® (lecanemab-irmb) for the treatment of MCI due to AD and mild AD dementia and highlight key considerations for clinical practice, including:

• Identifying appropriate patients for treatment with LEQEMBI
• Key efficacy and safety data from the Clarity AD study
• Important Safety Information, including Boxed WARNING for ARIA
• Guidance for screening and management of ARIA
• Navigating the steps from diagnosis to treatment with LEQEMBI

NON-Members or Followers invited.